Replies to post #253543 on Biotech Values

[DewDiligence]

ALT -55% on purportedly-positive phase-2b MASH data:

https://finance.yahoo.com/news/altimmune-announces-positive-topline-results-110000046.html

The effects on fibrosis improvement without worsening of MASH in an ITT analysis were 31.8% and 34.5% for pemvidutide 1.2 mg and 1.8 mg, respectively compared with 25.9% for placebo (differences not statistically significant).